for Adipose Tissue DIabetes VAriants (fATDIVA)
NCT02505321 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 304
Last updated 2018-06-21
Summary
The adipose (fat) cells under the skin are where individuals store excess fat. The more excess fat they have, the more "strain" they put on these cells which then get bigger and don't work as well as they should. Having some fat under the skin is important. People who have a genetic defect which results in them having almost no fat under their skin have a very high risk of a condition called insulin resistance (where the body does not respond as well to insulin and blood sugar levels rise). This can lead to diabetes and heart disease despite them not being overweight.
Scientists have only recently started to understand the importance of fat in insulin resistance and how people unable to store fat very well can have insulin resistance despite not being obese. The investigators have also recently discovered that small changes in a person's genetic code (their body's instruction manual) may also affect their ability to store fat and would like to explore this in more detail. To do this, they will recruit volunteers from the Exeter 10,000 study who gave permission to contact them about further research. The investigators will collect detailed body size measures and blood samples taken before and after a special drink that is high in fat (similar to a thick milk shake), then compare the results between people with and without the particular genetic changes of interest.
Knowing more about these genetic changes and how fat cells work could help to improve understanding about why some people develop diabetes and heart disease despite a relatively normal BMI.
Conditions
Interventions
- OTHER
-
Oral Triglyceride Tolerance Test (OTTT)
Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
- PROCEDURE
-
Abdominal fat biopsy (optional)
A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
Sponsors & Collaborators
-
University of Exeter
collaborator OTHER -
Royal Devon and Exeter NHS Foundation Trust
lead OTHER
Principal Investigators
-
Timothy M Frayling (Prof), PhD · University of Exeter
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-05-29
- Primary Completion
- 2017-10-31
- Completion
- 2017-10-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants
NCT01436201 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes
NCT03953963 ·Status: UNKNOWN ·Phase: NA
-
Effect of Adiposity on Hepatic and Peripheral Insulin Resistance in Type 1 Diabetes
NCT03582956 ·Status: TERMINATED ·Phase: NA
-
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
NCT02833415 ·Status: COMPLETED ·Phase: PHASE4
-
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
NCT03560323 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
NCT07313813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Metabolomic Analysis of Hepatic Insulin Resistance
NCT01833403 ·Status: COMPLETED ·Phase: NA
-
Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes
NCT00229268 ·Status: COMPLETED
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
NCT02262806 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
In Vitro Fertilization Impact on Metabolic Parameters
NCT03426228 ·Status: COMPLETED
-
Leptin to Treat Lipodystrophy
NCT00005905 ·Status: COMPLETED ·Phase: PHASE2
-
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Cardiovascular Effects.
NCT05236335 ·Status: COMPLETED ·Phase: NA
-
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
NCT04657939 ·Status: COMPLETED ·Phase: PHASE4
-
GLP-1 Receptor Targeting in Diabetic and Healthy Individuals
NCT01825148 ·Status: COMPLETED
-
Leptin to Treat Lipodystrophy
NCT00025883 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)
NCT01573949 ·Status: COMPLETED ·Phase: NA
-
52 Week Trial of Liraglutide in Type 1 Diabetes
NCT01787916 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance
NCT00004419 ·Status: COMPLETED ·Phase: NA
-
Low Dose Fat-Induced Insulin Resistance
NCT03479671 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
NCT02777073 ·Status: COMPLETED ·Phase: NA
-
Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
NCT02655770 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
NCT01761318 ·Status: COMPLETED ·Phase: PHASE4
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
NCT02262832 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Cardiovascular Effects of GLP-1 Receptor Activation
NCT03101930 ·Status: COMPLETED ·Phase: PHASE4
-
Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
NCT05541484 ·Status: COMPLETED ·Phase: PHASE4